Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Scandinavian Journal of Gastroenterology|October 25, 2018
Clinical effectiveness of golimumab in Crohn's disease: an observational study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG)Sara Rundquist, Carl Eriksson, Linda Nilsson, et al.
Clinical and Translational Gastroenterology|December 21, 2012
HLA-DR(hi) and CCR9 Define a Pro-Inflammatory Monocyte Subset in IBDLudvig Linton, Mats Karlsson, Jeanette Grundström, et al.
Gastroenterology|June 9, 2005
Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled studyGunnar Järnerot, Erik Hertervig, Ingalill Friis-Liby, et al.
Scandinavian Journal of Gastroenterology|March 1, 2007
Granulocyte, monocyte/macrophage apheresis for inflammatory bowel disease: the first 100 patients treated in ScandinaviaTryggve Ljung, Ole Østergaard Thomsen, Morten Vatn, et al.
Plos One|March 26, 2013
A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn's diseaseSatish Keshav, Tomáš Vaňásek, Yaron Niv, et al.
Therapeutic Advances in Gastroenterology|June 5, 2023
Long-term outcomes of vedolizumab in inflammatory bowel disease: the Swedish prospective multicentre SVEAH extension studyIsabella Visuri, Carl Eriksson, Sara Karlqvist, et al.
Scandinavian Journal of Gastroenterology|April 1, 2017
Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG)Carl Eriksson, Jan Marsal, Daniel Bergemalm, et al.
Therapeutic Advances in Gastroenterology|July 19, 2021
Real-world effectiveness of vedolizumab in inflammatory bowel disease: week 52 results from the Swedish prospective multicentre SVEAH studyCarl Eriksson, Sara Rundquist, Vyron Lykiardopoulos, et al.
Pageof 2